Synaptic Medical Secures $60 Million in Series G Funding

(VCBeat) Mar. 25, 2021 -- Synaptic Medical Inc. ("Synaptic Medical") recently completed a Series G financing of nearly US $60 million, led by Huagai Capital, with participation from YuanBio Venture Capital and the existing investor SIG, with Haoyue Capital serving as the exclusive financial adviser.

Founded in Minnesota in 2005 with a wholly-owned subsidiary in Beijing, Synaptic Medical is an innovative and international medical device company. The company focuses on developing and commercializing breakthrough products for the treatment of cardiac arrhythmias and other cardiovascular diseases.

At present, Synaptic Medical has more than 10 product lines for the diagnosis and treatment of arrhythmia diseases, which are applied in nearly 800 hospitals in China. At the same time, many types of its products have obtained registration certificates and being sold in the United States, the European Union and Japan, with recognition by local experts.

In 2020, Synaptic Medical set up an R&D center in California, USA, to develop side by side with the R&D team in China. In the growing-fast electrophysiology market, Synaptic Medical will rely on the R&D team with a global vision and continue to develop innovative products rapidly, with a deep understanding of the bottleneck of clinical application, to create high-performance products, and accelerate the pace of realizing substitution of imported products and internationalization.

Founded in 2012 and headquartered in Beijing, Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally, YuanBio Venture Capital focuses on early and growth-stage life science and healthcare investment. Its total AUM is close to 5 billion RMB. The portfolio includes over 70 companies across BioPharma, MedTech, IVD, and Health Services sectors. YuanBio Venture Capital aims to be one of the most successful healthcare venture capital firms in China.